Want to see TCRX full AI Analyst Report?
Top Page
TScan Therapeutics
(NASDAQ:TCRX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.76
▼(-4.30% Downside)
Action:Reiterated
Date:08/19/26
The score is primarily held down by weak financial performance (declining revenue, large ongoing losses, and persistent cash burn with rising leverage). Technicals also lean bearish with the stock below key moving averages and negative MACD. Valuation is difficult to support with a negative P/E, and corporate events are mixed, with the Amgen partnership termination weighing against positive clinical progress.
Positive Factors
Clinical Progress
The early TSC-101 clinical signal supports the therapy’s potential in hematologic malignancies. Sustained evidence of donor chimerism and acceptable safety could improve the program’s probability of advancing toward later-stage development.
Negative Factors
Partnership Loss
The Amgen termination weakens TScan’s partnership-driven revenue model by eliminating expected success-based economics from the collaboration. It reduces potential non-dilutive funding and increases reliance on internal programs and future financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Progress
The early TSC-101 clinical signal supports the therapy’s potential in hematologic malignancies. Sustained evidence of donor chimerism and acceptable safety could improve the program’s probability of advancing toward later-stage development.
Read all positive factors
TScan Therapeutics (TCRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$52.79M
Dividend YieldN/A
Average Volume (3M)476.93K
Price to Earnings (P/E)―
Beta (1Y)2.05
Revenue Growth2.15%
EPS Growth17.34%
CountryUS
Employees139
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,502,666
10 Day Avg. Volume455,904
30 Day Avg. Volume476,927
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside659.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$7.86M
TScan Therapeutics Business Overview & Revenue Model
Company Description
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment...
How the Company Makes Money
TScan Therapeutics generates revenue primarily from research and development collaboration and license agreements rather than from product sales, as it is a clinical-stage company and does not have broadly commercialized, marketed therapies. Under...
TScan Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.11M | 10.32M | 2.82M | 21.05M | 13.54M | 10.14M |
| Gross Profit | 6.42M | 7.46M | 2.82M | 21.05M | 13.54M | 10.14M |
| EBITDA | -112.04M | -124.13M | -119.74M | -80.10M | -59.91M | -45.30M |
| Net Income | -117.71M | -129.77M | -127.50M | -89.22M | -66.22M | -48.63M |
Balance Sheet | ||||||
| Total Assets | 171.45M | 228.79M | 371.12M | 272.15M | 199.09M | 188.11M |
| Cash, Cash Equivalents and Short-Term Investments | 100.16M | 152.41M | 290.11M | 192.04M | 120.03M | 161.41M |
| Total Debt | 90.89M | 94.14M | 97.38M | 92.43M | 85.98M | 6.04M |
| Total Liabilities | 102.43M | 105.67M | 130.15M | 121.28M | 99.66M | 27.33M |
| Stockholders Equity | 69.02M | 123.12M | 240.97M | 150.87M | 99.43M | 160.78M |
Cash Flow | ||||||
| Free Cash Flow | -118.44M | -139.73M | -114.65M | -64.50M | -70.73M | -58.62M |
| Operating Cash Flow | -116.28M | -135.32M | -110.82M | -61.36M | -66.50M | -48.68M |
| Investing Cash Flow | 46.87M | 109.37M | -52.61M | -60.76M | -4.22M | -9.94M |
| Financing Cash Flow | 172.00K | -336.00K | 208.76M | 135.44M | 29.36M | 189.67M |
TScan Therapeutics Technical Analysis
Negative
0.79
Price Trends
0.89
Negative
1.00
Negative
1.04
Negative
Market Momentum
-0.04
Negative
43.23
Neutral
65.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRX, the sentiment is Negative. The current price of 0.79 is above the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.89, and below the 200-day MA of 1.04, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 43.23 is Neutral, neither overbought nor oversold. The STOCH value of 65.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRX.
TScan Therapeutics Risk Analysis
TScan Therapeutics disclosed 108 risk factors in its most recent earnings report. TScan Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TScan Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $336.28M | -5.03 | -42.80% | ― | ― | 59.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $271.02M | -1.74 | -90.30% | ― | ― | 48.20% | |
47 Neutral | $50.05M | -1.65 | -39.76% | ― | ― | 65.39% | |
45 Neutral | $281.62M | -0.58 | 187.62% | ― | -8.79% | -195.46% | |
43 Neutral | $52.79M | -0.86 | -108.72% | ― | 2.15% | 17.34% | |
42 Neutral | $255.15M | -1.51 | -87.95% | ― | -100.00% | 14.08% |
* Healthcare Sector Average
TCRX
TScan Therapeutics
0.78
-0.90
-53.39%
ZNTL
Zentalis Pharmaceuticals
3.71
2.12
133.02%
ALXO
ALX Oncology Holdings
1.97
1.08
121.35%
IKT
Inhibikase Therapeutics
2.39
0.69
40.59%
SRZN
Surrozen
23.78
12.63
113.27%
TIL
Instil Bio
7.36
-18.14
-71.14%
TScan Therapeutics Corporate Events
Business Operations and Strategy
TScan Therapeutics Faces Loss of Key Amgen Partnership
Negative
Aug 18, 2026
On August 12, 2026, TScan Therapeutics said that Amgen had exercised its right to terminate their May 8, 2023 research collaboration and license agreement focused on using TScan’s target discovery platform to identify T-cell antigens in Croh...
Business Operations and StrategyProduct-Related Announcements
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
Positive
Jun 22, 2026
On June 22, 2026, TScan Therapeutics reported initial data from Cohort C of its ongoing ALLOHA Phase 1 trial evaluating TSC-101, produced with a commercial-ready manufacturing process, in patients with hematologic malignancies undergoing allogenei...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
Positive
May 22, 2026
On May 20, 2026, TScan Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Katina Dorton and R. Keith Woods as Class II directors to three-year terms ending in 2029 and ratified Deloitte Touche LLP as the i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.